Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Addington

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|September 1, 1992
Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelinesE J Collins, P Lalonde, B D Jones, et al.
Journal of Clinical Psychopharmacology|February 1, 1993
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsG Chouinard, B Jones, G Remington, et al.
Archives of General Psychiatry|March 11, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophreniaS E Purdon, B D Jones, E Stip, et al.
Schizophrenia Research|March 30, 2001
The Schizophrenia Suicide Risk Scale (SSRS): development and initial validationT Taiminen, J Huttunen, H Heilä, et al.
Schizophrenia Research|March 22, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sampleT J Miller, R B Zipursky, D Perkins, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|September 1, 1992
Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelinesE J Collins, P Lalonde, B D Jones, et al.
Journal of Clinical Psychopharmacology|February 1, 1993
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patientsG Chouinard, B Jones, G Remington, et al.
Archives of General Psychiatry|March 11, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophreniaS E Purdon, B D Jones, E Stip, et al.
Schizophrenia Research|March 30, 2001
The Schizophrenia Suicide Risk Scale (SSRS): development and initial validationT Taiminen, J Huttunen, H Heilä, et al.
Schizophrenia Research|March 22, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sampleT J Miller, R B Zipursky, D Perkins, et al.
Pageof 7